Biosimilars | Association for Accessible Medicines

Top 10 Ways to Commemorate 10 Years of Biosimilars in the U.S.

U.S. biosimilar medicines are 10 years old this year. It’s been an amazing journey so far, and we see great promise and opportunity ahead, with greater access and lower prices for patients with cancer, Crohn’s disease, rheumatoid arthritis and other conditions. Here are 10 ways to mark this auspicious anniversary:

10. Learn more about the 10th anniversary of the Biologics Price Competition and Innovation Act (BPCIA) at www.b10similars.org.

Read more about Top 10 Ways to Commemorate 10 Years of Biosimilars in the U.S.

Jeni Got Her Life Back, Thanks to a Biosimilar

In 2019, Jeni Doerr finally received a diagnosis for her recent illnesses – pancolitis. Doerr, 35, from Newhall, CA, is featured in AAM’s recently released 2020 Generic Drug & Biosimilars Access & Savings in the U.S. report.

Read more about Jeni Got Her Life Back, Thanks to a Biosimilar

Jeni's Story — Biosimilars Savings

Submitted by eklinger on Thu, 10/08/2020 - 14:11

Jeni Doerr, 35, has recently gone back to school to become a medical coder and when she is not online learning, she is outside enjoying everything California has to offer through hiking, rock climbing and mountain biking with her dog Sally. Jeni takes the biosimilar Inflectra for her pancolitis. She had previously taken a brand biologic, but it didn’t do anything for her symptoms.

"If I'd known I could be on a biosimilar, I'd have done it immediately." —Jeni, Santa Clarita, CA

Celebrate a decade of biosimilar savings at https://b10similars.org/.

Read more about Jeni's Story — Biosimilars Savings

Christine Simmon: Policy and Biosimilars Sessions at the GRx+Biosims 2020 Virtual Conference

Submitted by eklinger on Thu, 09/10/2020 - 08:30

GRx+Biosims is going virtual, join us from around the globe on November 9-11, 2020. You can look forward to the same impactful and news making content you have experienced at past GRx+Biosims events. If you care about generic and biosimilar development, the regulatory process and approvals, and the evolving policy landscape, this is the one conference you cannot afford to miss.

We’ll have:

Read more about Christine Simmon: Policy and Biosimilars Sessions at the GRx+Biosims 2020 Virtual Conference

AAM Commends Introduction of the Increasing Access to Biosimilars Act

WASHINGTON, DC (July 2, 2020) — AAM and its Biosimilars Council commend Senators Cornyn and Bennet for introduction of the Increasing Access to Biosimilars Act. This bipartisan proposal is based on a simple idea – that Medicare policies should encourage the use of the most effective, lowest-cost medicine. Biosimilars consistently deliver savings compared to high-priced brand biologics. We encourage Congress and the Administration to quickly implement this policy and deliver savings to America’s patients and taxpayers.

Read more about AAM Commends Introduction of the Increasing Access to Biosimilars Act

AAM Files Amicus Brief Supporting the BPCIA

WASHINGTON, DC (May 14, 2020) — The Association for Accessible Medicines (AAM) has filed an amicus brief in the latest constitutional challenge to the Affordable Care Act (ACA), arguing that even if the individual mandate of the ACA is deemed unconstitutional, the biosimilars pathway (BPCIA) should survive.

Read more about AAM Files Amicus Brief Supporting the BPCIA

USMCA: Nothing to See Here (Infographic)

Brand-name drug companies claim that without USMCA, there's no market for biologics in Mexico. But, the world's largest pharmaceutical companies launched their top-selling biologics in Mexico. Learn more in this infographic:

Read more about USMCA: Nothing to See Here (Infographic)

Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA

The pharmaceutical provisions included in the negotiated text of the U.S.-Mexico-Canada Agreement will do many things. But creating a market for biologics in Mexico is not one of them. Why? Because pharmaceutical companies have been selling original biologics in Mexico since before 2001.

Read more about Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA

White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption

America’s health care system is eager for biosimilars, especially in light of mounting evidence that they deliver increased patient access and savings by providing competition for costly brand-name biologics.

Read more about White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption

AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

Submitted by eklinger on Mon, 09/09/2019 - 11:14

Karin Hessler, Assistant General Counsel at the Association for Accessible Medicines, urges attendees to add their voice to the discussion at the one essential generic and biosimilar conference of the year: GRx+Biosims 2019, November 4—6 in Bethesda, MD.

The conference legal track:

Read more about AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

Subscribe to Biosimilars